nephropathy. Diabetic nephropathy
Conditions
Interventions
Intervention 1: The intervention group 1: oral N-acetylcysteine with standard dose + 0/9% saline infusion: Received oral N-acetylcysteine, 600 mg daily, twice a day for two days (the day before receiv
Treatment - Drugs
The intervention group 1: oral N-acetylcysteine with standard dose + 0/9% saline infusion: Received oral N-acetylcysteine, 600 mg daily, twice a day for two days (the day before receiving the contrast
The intervention group 2: oral N-acetylcysteine with twice the standard dose + 0/9% saline infusion: Received oral N-acetylcysteine, 1200 mg daily, twice a day for two days (the day before receiving t
Sponsors
Semnan University of Medical Sciences, Vice Chancellor for Research and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: aged 18 and older; glomerular filtration rate less than 60 ml. Exclusion criteria: pregnant women; lactating mother; dialysis patients; blood pressure; baseline serum creatinine level greater than 7 mg/dL; severe valvular heart disease; autoimmune disorders; acute or chronic diseases; get contrast media in 10 days ago; sensitivity to contrast media or N-acetylcysteine; oliguria (the urine volume less than 400 cc in 24 hours); acute heart failure with preserved ejection fraction <35%; receive supplements of vitamin C in the past week.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum creatinine levels. Timepoint: Before the intervention, 24, 48 and 72 hours after the intervention. Method of measurement: Laboratory.;BUN levels. Timepoint: Before the intervention, 24, 48 and 72 hours after the intervention. Method of measurement: Laboratory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Maryam Tavallaei
Semnan University of Medical Sciences
Outcome results
None listed